NCT00652431View on ClinicalTrials.gov

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
HypercholesterolemiaHyperlipidemia
Interventions
DRUG

Vytorin + Niaspan

Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7

DRUG

Vytorin

Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days

DRUG

Niaspan

Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00652431 - Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2) | Biotech Hunter | Biotech Hunter